Monday, July 24, 2017

Press Release

March 13, 2015 by  
Filed under Depression

DUBLIN March 13 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for SAPHRIS® (asenapine) as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 – 17). SAPHRIS is the only atypical antipsychotic ...

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!